^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SL-172154
i
Other names: SL-172154, SIRPα-Fc-CD40L, SL172154, SL 172154
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Shattuck
Drug class:
CD47 inhibitor, CD40 agonist
Related drugs:
13d
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. (PubMed, Br J Cancer)
Combination of SL172154 with MIRV did not improve upon the previously reported ORR for MIRV, while the combination with PLD resulted in a higher ORR than reported for PLD, albeit in a small number of patients. Limited tumor penetration of SL-172154, lack of durable CD47 blockade, inability to overcome T cell exhaustion and other mechanisms of resistance may explain these findings. Trial register number: NCT05483933.
P1 data • Journal • Platinum resistant
|
FOLR1 ( Folate receptor alpha ) • CD40 (CD40 Molecule)
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
1m
SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=106, Terminated, Shattuck Labs, Inc. | Completed --> Terminated; Development discontinued
Trial termination
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
1year
SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
P1, N=86, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
Trial completion • Trial completion date • Trial primary completion date
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
1year
SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov)
P1, N=106, Completed, Shattuck Labs, Inc. | Active, not recruiting --> Completed | N=160 --> 106 | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Nov 2024 --> Feb 2025
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
over1year
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. (PubMed, J Immunother Cancer)
SL-172154 was tolerable as monotherapy and induced, dose-dependent, and cyclical immune cell activation, increases in multiple serum cytokines, and trafficking of CD40-positive B cells and monocytes following each infusion. The safety, PK, and PD activity support 3.0 mg/kg as a safe and pharmacologically active dose.
P1 data • Journal
|
CD8 (cluster of differentiation 8) • CD40 (CD40 Molecule) • CD40LG (CD40 ligand) • SIRPA (Signal Regulatory Protein Alpha)
|
SL-172154
over1year
SL03-OHD-105: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers (clinicaltrials.gov)
P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial completion date: Apr 2025 --> Nov 2024
Trial completion date
|
FOLR1 ( Folate receptor alpha )
|
FOLR1 expression
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
over1year
SL03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML (clinicaltrials.gov)
P1, N=160, Active, not recruiting, Shattuck Labs, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Nov 2024 | Trial primary completion date: Apr 2025 --> Nov 2024
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
over1year
SL03-OHD-105: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Trial primary completion date: Jul 2024 --> Dec 2024
Trial primary completion date
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
almost2years
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1, N=86, Active, not recruiting, Shattuck Labs, Inc. | Enrolling by invitation --> Active, not recruiting
Enrollment closed
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
2years
03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=160, Recruiting, Shattuck Labs, Inc. | N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
over2years
03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=107, Recruiting, Shattuck Labs, Inc.
Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
over2years
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers (clinicaltrials.gov)
P1, N=102, Enrolling by invitation, Shattuck Labs, Inc. | Recruiting --> Enrolling by invitation | Phase classification: P1b --> P1
Enrollment status • Phase classification
|
FOLR1 ( Folate receptor alpha )
|
pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154
Share via
